Raloxifene inhibits the overexpression of TGF-β1 in cartilage and regulates the metabolism of subchondral bone in rats with osteoporotic osteoarthritis

Authors

  • Shao-Hua Ping Department of Orthopedic Surgery, Hebei Medical University, Shijiazhuang, China https://orcid.org/0000-0002-2560-851X
  • Fa-Ming Tian Medical Research Center, North China University of Science and Technology, Tangshan, China
  • Hao Liu Department of Orthopedic Surgery, Affiliated Hospital of North China University of Science and Technology, Tangshan, China https://orcid.org/0000-0003-0994-1256
  • Qi Sun Department of Orthopedic Surgery, Hebei Medical University, Shijiazhuang, China https://orcid.org/0000-0002-2679-9960
  • Li-Tao Shao Department of Orthopedic Surgery, Hebei Medical University, Shijiazhuang, China https://orcid.org/0000-0003-0962-3266
  • Qiang-Qiang Lian Department of Orthopedic Surgery, the Affiliated Hospital of North China University of Science and Technology, Tangshan, China
  • Liu Zhang Department of Orthopedic Surgery, Hebei Medical University, Shijiazhuang, China; Department of Orthopedic Surgery, Emergency General Hospital, Beijing, China https://orcid.org/0000-0001-5239-3561

DOI:

https://doi.org/10.17305/bjbms.2020.5142

Keywords:

Osteoporosis, osteoarthritis, raloxifene, TGF-β1, cartilage, subchondral bone

Abstract

Overexpression of transforming growth factor-beta 1 (TGF-β1) and subchondral bone remodelling play key roles in osteoarthritis (OA). Raloxifene (RAL) reduces the serum level of TGF-β1 in postmenopausal women. However, the effect of RAL on TGF-β1 expression in articular cartilage is still unclear. Therefore, we aimed to investigate the protective effect of RAL on osteoporotic osteoarthritis via affecting TGF-β1 expression in cartilage and the metabolism of subchondral bone. Osteoporotic osteoarthritis was induced by a combination of anterior cruciate transection (ACLT) and ovariectomy (OVX). Rats were divided into five groups (n = 12): The sham group, the ACLT group, the OVX group, the ACLT + OVX group, and the RAL group (ACLT + OVX + RAL, 6.25 mg/kg/day for 12 weeks). Assessment was performed by histomorphology, microcomputed tomography (micro-CT) scan, immunohistochemistry, and tartrate-resistant acid phosphatase (TRAP) staining. We found that severe cartilage degeneration was shown in the ACLT + OVX group. The histomorphological scores, the levels of TGF-β1, and its related catabolic enzymes and osteoclasts numbers in the ACLT + OVX group were higher than those in other groups (p < 0.05). Furthermore, structure model index (SMI) and trabecular spacing (Tb.Sp) were decreased (p < 0.05), while bone mineral density (BMD), bone volume fraction (BV/TV), and trabecular number (Tb.N) were increased by RAL compared with the ACLT + OVX group (p < 0.05). Our findings demonstrated that RAL in clinical doses retards the development of osteoporotic osteoarthritis by inhibiting the overexpression of TGF-β1 in cartilage and regulating the metabolism of subchondral bone. These results provide support for RAL in the expansion of clinical indication for prevention and treatment in postmenopausal osteoarthritis.

Raloxifene inhibits the overexpression of TGF-β1 in cartilage and regulates the metabolism of subchondral bone in rats with osteoporotic osteoarthritis

Downloads

Additional Files

Published

01-06-2021

How to Cite

1.
Raloxifene inhibits the overexpression of TGF-β1 in cartilage and regulates the metabolism of subchondral bone in rats with osteoporotic osteoarthritis. Biomol Biomed [Internet]. 2021 Jun. 1 [cited 2024 Feb. 22];21(3):284-93. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/5142

Funding data